Hepatitis C

Hepatitis C is a global health problem, and an estimated 71·1 million individuals are chronically infected with hepatitis C virus (HCV). The global incidence of HCV was 23·7 cases per 100 000 population (95% uncertainty interval 21·3–28·7) in 2015, with an estimated 1·75 million new HCV infections d...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2019-10, Vol.394 (10207), p.1451-1466
Main Authors: Spearman, C Wendy, Dusheiko, Geoffrey M, Hellard, Margaret, Sonderup, Mark
Format: Article
Language:English
Subjects:
Antiviral agents
Antiviral drugs
Blood transfusion
Cirrhosis
Diagnosis
Epidemiology
Gays & lesbians
Genotype & phenotype
Genotypes
Global health
Health care access
Hepatitis
Hepatitis C
Hepatitis C - diagnosis
Hepatitis C - epidemiology
Hepatitis C - therapy
Hepatocellular carcinoma
HIV
Human immunodeficiency virus
Humans
Infections
Liver cirrhosis
Liver diseases
Mens health
Narcotics
Prisoners
Risk factors
Therapy
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatitis C is a global health problem, and an estimated 71·1 million individuals are chronically infected with hepatitis C virus (HCV). The global incidence of HCV was 23·7 cases per 100 000 population (95% uncertainty interval 21·3–28·7) in 2015, with an estimated 1·75 million new HCV infections diagnosed in 2015. Globally, the most common infections are with HCV genotypes 1 (44% of cases), 3 (25% of cases), and 4 (15% of cases). HCV transmission is most commonly associated with direct percutaneous exposure to blood, via blood transfusions, health-care-related injections, and injecting drug use. Key high-risk populations include people who inject drugs, men who have sex with men, and prisoners. Approximately 10–20% of individuals who are chronically infected with HCV develop complications, such as cirrhosis, liver failure, and hepatocellular carcinoma over a period of 20–30 years. Direct-acting antiviral therapy is now curative, but it is estimated that only 20% of individuals with hepatitis C know their diagnosis, and only 15% of those with known hepatitis C have been treated. Increased diagnosis and linkage to care through universal access to affordable point-of-care diagnostics and pangenotypic direct-acting antiviral therapy is essential to achieve the WHO 2030 elimination targets.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(19)32320-7